Curcumin and lung cancer--a review.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Works matching IS 17762596 AND DT 2014 AND VI 9 AND IP 4
Results: 14
1
2
Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
- Published in:
- 2014
- By:
- Publication type:
- journal article
3
Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER- 2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 367, doi. 10.1007/s11523-013-0297-2
- By:
- Publication type:
- Article
4
Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 359, doi. 10.1007/s11523-013-0298-1
- By:
- Publication type:
- Article
5
Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 349, doi. 10.1007/s11523-013-0300-y
- By:
- Publication type:
- Article
6
Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 321, doi. 10.1007/s11523-014-0305-1
- By:
- Publication type:
- Article
7
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 331, doi. 10.1007/s11523-014-0306-0
- By:
- Publication type:
- Article
8
Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 339, doi. 10.1007/s11523-014-0309-x
- By:
- Publication type:
- Article
9
Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 381, doi. 10.1007/s11523-014-0312-2
- By:
- Publication type:
- Article
10
EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 389, doi. 10.1007/s11523-014-0314-0
- By:
- Publication type:
- Article
11
Curcumin and lung cancer-a review.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 295, doi. 10.1007/s11523-014-0321-1
- By:
- Publication type:
- Article
12
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 395, doi. 10.1007/s11523-014-0327-8
- By:
- Publication type:
- Article
13
ESMO 2014: new trends in precision medicine.
- Published in:
- 2014
- By:
- Publication type:
- Editorial
14
Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort.
- Published in:
- Targeted Oncology, 2014, v. 9, n. 4, p. 311, doi. 10.1007/s11523-013-0296-3
- By:
- Publication type:
- Article